X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adult (5) 5
female (5) 5
humans (5) 5
male (5) 5
aged (4) 4
care and treatment (4) 4
index medicus (4) 4
middle aged (4) 4
treatment outcome (4) 4
antineoplastic agents - therapeutic use (3) 3
double-blind method (3) 3
drug therapy (3) 3
metastasis (3) 3
oncology (3) 3
aged, 80 and over (2) 2
analysis (2) 2
basal cell carcinoma (2) 2
biphenyl compounds - administration & dosage (2) 2
biphenyl compounds - adverse effects (2) 2
cancer (2) 2
carcinoma, basal cell - drug therapy (2) 2
clinical trials (2) 2
everolimus (2) 2
guidelines (2) 2
management (2) 2
medical research (2) 2
medicine, experimental (2) 2
mtor inhibitor (2) 2
neoplasm metastasis (2) 2
open-label (2) 2
patient outcomes (2) 2
pyridines - administration & dosage (2) 2
pyridines - adverse effects (2) 2
sirolimus - analogs & derivatives (2) 2
sirolimus - therapeutic use (2) 2
skin (2) 2
skin neoplasms - drug therapy (2) 2
skin neoplasms - pathology (2) 2
therapy (2) 2
vismodegib (2) 2
young adult (2) 2
610 medicine & health (1) 1
advanced basal cell carcinoma (1) 1
advanced solid tumors (1) 1
anemia (1) 1
angiogenesis inhibitors (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - pharmacokinetics (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
asian (1) 1
asian continental ancestry group (1) 1
basal cell carcinoma outcomes with lde225 treatment study (1) 1
bevacizumab (1) 1
biphenyl compounds (1) 1
biphenyl compounds - therapeutic use (1) 1
cancer research (1) 1
cancer therapies (1) 1
carboplatin - administration & dosage (1) 1
carboplatin - adverse effects (1) 1
carboplatin - pharmacokinetics (1) 1
carboplatin - therapeutic use (1) 1
carcinoma, basal cell (1) 1
carcinoma, basal cell - pathology (1) 1
carcinoma, basal cell - radiotherapy (1) 1
carcinoma, basal cell - secondary (1) 1
carcinoma, basal cell - surgery (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, non-small-cell lung - pathology (1) 1
carcinoma, renal cell (1) 1
carcinoma, renal cell - drug therapy (1) 1
carcinoma, renal cell - mortality (1) 1
carcinoma, renal cell - pathology (1) 1
case studies (1) 1
chemotherapy, combination (1) 1
china (1) 1
combination (1) 1
corn (1) 1
demography (1) 1
dermatology (1) 1
dermatology clinic (1) 1
development and progression (1) 1
diabetes (1) 1
diabetes therapy (1) 1
diabetic neuropathies - physiopathology (1) 1
diabetic neuropathies - radiotherapy (1) 1
disease progression (1) 1
disease-free survival (1) 1
dose-escalation (1) 1
dose-limiting toxicity (1) 1
dose-response relationship, drug (1) 1
double-blind (1) 1
drug administration schedule (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 716 - 728
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 113 - 125.e5
Background The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell... 
Dermatology | Basal Cell Carcinoma Outcomes with LDE225 Treatment study | hedgehog pathway inhibitor | sonidegib | locally advanced basal cell carcinoma | metastatic basal cell carcinoma | advanced basal cell carcinoma | Locally advanced basal cell carcinoma | Advanced basal cell carcinoma | Metastatic basal cell carcinoma | Sonidegib | Hedgehog pathway inhibitor | HEDGEHOG PATHWAY | MULTICENTER | VISMODEGIB | MANAGEMENT | EFFICACY | GUIDELINES | OPEN-LABEL | DERMATOLOGY | DOSE-ESCALATION | UPDATE | INHIBITOR | Skin Neoplasms - drug therapy | Humans | Middle Aged | Carcinoma, Basal Cell - secondary | Biphenyl Compounds - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Biphenyl Compounds - therapeutic use | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Smoothened Receptor - antagonists & inhibitors | Pyridines - therapeutic use | Skin Neoplasms - pathology | Pyridines - administration & dosage | Double-Blind Method | Survival Rate | Disease Progression | Biphenyl Compounds - administration & dosage | Carcinoma, Basal Cell - drug therapy | Aged | Medical research | Care and treatment | Basal cell carcinoma | Analysis | Patient outcomes | Corn | Medicine, Experimental | Skin | Metastasis | Drug therapy | Cancer
Journal Article
Diabetes Care, ISSN 0149-5992, 04/2004, Volume 27, Issue 4, p. 921
Low-Intensity Laser Therapy for Painful Symptoms of Diabetic Sensorimotor Polyneuropathy A controlled trial Lorne H. Zinman , FRCPC , Mylan Ngo , BSC , Eduardo... 
Journal Article
BMC Cancer, ISSN 1471-2407, 03/2013, Volume 13, Issue 1, pp. 136 - 136
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2014, Volume 32, Issue 1, pp. 123 - 134
Introduction One standard of care for advanced non–small cell lung cancer (NSCLC) is paclitaxel plus carboplatin ± bevacizumab. This two-step phase I study... 
Oncology | Medicine & Public Health | Pharmacology/Toxicology | Everolimus | Dose-limiting toxicity | Non-small cell lung cancer | MAMMALIAN TARGET | ADVANCED SOLID TUMORS | THERAPY | ONCOLOGY | PHARMACOLOGY & PHARMACY | MODEL | COMBINATION | MTOR INHIBITOR | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Demography | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Carboplatin - pharmacokinetics | Paclitaxel - pharmacokinetics | Bevacizumab | Feasibility Studies | Carboplatin - adverse effects | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carboplatin - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacokinetics | Adult | Female | Paclitaxel - administration & dosage | Sirolimus - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Treatment Outcome | Sirolimus - pharmacokinetics | Paclitaxel - therapeutic use | Sirolimus - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Chemotherapy, Combination | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Methods | Studies | Clinical trials | Cancer therapies | Lung cancer | Pharmaceutical sciences | Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 04/2004, Volume 27, Issue 4, pp. 921 - 924
Journal Article
CMAJ, ISSN 0820-3946, 06/2005, Volume 172, Issue 13, pp. 1682 - 1682
  Design: A randomized, multi-centre trial was conducted by the Scandinavian Prostate Cancer Group, beginning in 1989. A total of 695 patients no older than 75... 
MEDICINE, GENERAL & INTERNAL | RADICAL PROSTATECTOMY | Evaluation | Care and treatment | Prostate cancer | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.